PROFESSIONAL EDITION

The largest community of pharma leaders

Gamida Cell Announces Positive Topline Data on Secondary Endpoints from Phase 3 Clinical Study of Omidubicel in Patients with Hematologic Malignancies

BOSTON–(BUSINESS WIRE)—- $GMDA #BMT–Gamida Cell announced that its Phase 3 clinical study of omidubicel in bone marrow transplant met all three secondary endpoints.

Source

Recent Articles